CKD Bio Q3 Revenue Falls 14% Year on Year
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
AstraZeneca Reports Q3 Revenue of $16.21 Billion; Oncology Rises 17%
The headline also reports a decline for Farxiga and an Etcamah miss; it does not specify what Etcamah missed.
M impact | EQUITY | Oct 31, 2026, 08:04 AM UTC
BP Posts Record Q3 Profit, Cuts Net Debt to $13.9 Billion
M impact | EQUITY | Oct 31, 2026, 08:01 AM UTC
TTE Plans Buybacks, Sets Gas Target and 50% OPL257 Interest
The headline says TTE plans buybacks, targets an additional 1 Bcf/d of gas and has a 50% interest in OPL257; no further details are provided.
M impact | EQUITY | Oct 31, 2026, 08:01 AM UTC
Mondelez Expects Chocolate Sales to Accelerate in Brazil After Price Increases
M impact | EQUITY | Oct 31, 2026, 07:41 AM UTC
Kenvue Reports Higher Third-Quarter Profit and Revenue, Awaits Kimberly-Clark Deal Closing
Kenvue reported increases in profit and revenue for the third quarter and is awaiting completion of its acquisition by Kimberly-Clark.
M impact | EQUITY | Oct 31, 2026, 07:41 AM UTC
Alphabet Q3 Revenue $127.6B; Free Cash Flow Negative
M impact | EQUITY | Oct 31, 2026, 07:02 AM UTC